Bharat Biotech’s Covaxin has shown 77.8 per cent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed its Phase III trials data on Tuesday, according to sources.
The Hyderabad-based COVID vaccine manufacturing company had submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend.
Bharat Biotech’s ‘pre-submission’ meeting with the World Health Organization (WHO) will take on Wednesday for the approval for Covaxin.
Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine has been questioned various times and this is what makes the data that ascertains the efficacy of the vaccine crucial.
The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR). (ANI)
In total, around 1,200-1,400 houses primarily belonging to Bengali-speaking Muslims, were demolished during the eviction…
Archery World Cup final featured eight archers in men's and women's categories across both recurve…
The last date for filing of nominations is October 25 and the last date for…
The summit ends on 24th October but the Prime Minister on account of pressing commitments…
Sakshi Biswakarma will go on to represent Assam at the upcoming Miss Northeast and other…
Serene Production has acquired a 50 per cent stake in Karan Johar's Dharma Productions and Dharmatic…